UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
OF THE SECURITIES EXCHANGE ACT OF 1934
FOR THE MONTH OF MAY 2021
COMMISSION FILE NUMBER 001-38976
Genmab A/S
(Exact name of Registrant as specified in its charter)
Kalvebod Brygge 43
1560 Copenhagen V
Denmark
+45 70 20 27 28
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F ⌧ Form 40-F ◻
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1)
Yes ◻ No ⌧
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7)
Yes ◻ No ⌧
This report on Form 6-K shall be deemed to be incorporated by reference in Genmab A/S’s registration statements on Form S-8 (File No. 333-232693) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| GENMAB A/S | |
| | |
| BY: | /s/ Anthony Pagano |
| | Name: Anthony Pagano |
| | Title: Executive Vice President & Chief Financial Officer |
DATE: May 7, 2021
EXHIBIT INDEX
Exhibit | Description of Exhibit |
| |
99.1 | Company Announcement Dated May 7, 2021: Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons |
Exhibit 99.1
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
Company Announcement
COPENHAGEN, Denmark; May 07, 2021 – Genmab A/S (Nasdaq: GMAB) In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the transactions made in Genmab A/S (Nasdaq: GMAB) made by managerial employees and their closely associated persons.
The company’s managerial employees and their closely associated persons have given Genmab A/S power of attorney on their behalf to publish trading in Genmab shares by the company’s managerial employees and their closely associated persons.
The sale of shares by Jan van de Winkel is partly to honor tax obligations arising out of his participation in Genmab A/S’ equity program. The sale of shares will take Jan van de Winkel’s personal holding of shares in Genmab A/S from 645,460 to 610,460 shares.
Please find below a statement of such trading in shares issued by Genmab A/S
1. | Details of the person discharging managerial responsibilities / | ||
a) | Name | Jan van de Winkel | |
2. | Reason for the notification | ||
a) | Position/status | President and Chief Executive Officer | |
b) | Initial notification/Amendment | Initial notification | |
3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
a) | Name | Genmab A/S | |
b) | LEI-code | 529900MTJPDPE4MHJ122 | |
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
a) | Description of the financial instrument, type of instrument Identification code | Share DK0010272202 | |
b) | Nature of the transaction | Sale of shares | |
c) | Price(s) and volumes(s) | Price(s) | Volumes(s) |
DKK 2,252 | 40 | ||
DKK 2,253 | 208 | ||
DKK 2,254 | 242 | ||
DKK 2,255 | 664 | ||
DKK 2,256 | 820 | ||
Genmab A/S | Tel: +45 7020 2728 | Company Announcement no. 37 |
Kalvebod Brygge 43 | www.genmab.com | Page 1/4 |
1560 Copenhagen V, Denmark | | CVR no. 2102 3884 |
| | LEI Code 529900MTJPDPE4MHJ122 |
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
| | DKK 2,257 | 2,751 |
DKK 2,258 | 1,414 | ||
DKK 2,259 | 973 | ||
DKK 2,260 | 881 | ||
DKK 2,261 | 886 | ||
DKK 2,262 | 1,585 | ||
DKK 2,263 | 869 | ||
DKK 2,264 | 924 | ||
DKK 2,265 | 964 | ||
DKK 2,266 | 709 | ||
DKK 2,267 | 1,334 | ||
DKK 2,268 | 693 | ||
DKK 2,269 | 789 | ||
DKK 2,269.50 | 27 | ||
DKK 2,270 | 580 | ||
DKK 2,270.50 | 578 | ||
DKK 2,271 | 1,785 | ||
DKK 2,271.50 | 502 | ||
DKK 2,272 | 661 | ||
DKK 2,272.50 | 57 | ||
DKK 2,273 | 501 | ||
DKK 2,273.50 | 148 | ||
DKK 2,274 | 1,562 | ||
DKK 2,274.50 | 106 | ||
DKK 2,275 | 754 | ||
DKK 2,275.50 | 79 | ||
DKK 2,276 | 288 | ||
DKK 2,276.50 | 56 | ||
DKK 2,277 | 1,716 | ||
DKK 2,278 | 1,199 | ||
DKK 2,279 | 275 | ||
DKK 2,280 | 404 | ||
DKK 2,281 | 428 | ||
DKK 2,282 | 375 | ||
DKK 2,283 | 645 | ||
DKK 2,284 | 372 | ||
DKK 2,285 | 526 | ||
DKK 2,286 | 377 | ||
DKK 2,287 | 169 | ||
DKK 2,288 | 275 | ||
DKK 2,289 | 482 | ||
DKK 2,290 | 1,145 | ||
DKK 2,291 | 1,140 |
Genmab A/S | Tel: +45 7020 2728 | Company Announcement no. 37 |
Kalvebod Brygge 43 | www.genmab.com | Page 2/4 |
1560 Copenhagen V, Denmark | | CVR no. 2102 3884 |
| | LEI Code 529900MTJPDPE4MHJ122 |
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
| | DKK 2,292 | 556 |
DKK 2,293 | 304 | ||
DKK 2,294 | 163 | ||
DKK 2,295 | 19 | ||
d) | Aggregated information | 35,000 DKK 2,270.68 | |
e) | Date of the transaction | 2021-05-07 | |
f) | Place of the transaction | Aquis Exchange (AQEU) CBOE Europe (BEUP, CEUD and CEUX) Citadel Connect (EUCC) Hrteu (HREU) Morgan Stanley (MESI) Nasdaq Copenhagen (DCSE, MCSE and XCSE) Posit (XPAC and XPOS) Sigma (SGMV) Tower Research Capital Europe (TOWR) Turquoise (TQEM and TQEX) | |
About Genmab
Genmab is an international biotechnology company with a core purpose to improve the lives of patients with cancer. Founded in 1999, Genmab is the creator of multiple approved antibody therapeutics that are marketed by its partners. The company aims to create, develop and commercialize differentiated therapies by leveraging next-generation antibody technologies, expertise in antibody biology, translational research and data sciences and strategic partnerships. To create novel therapies, Genmab utilizes its next-generation antibody technologies, which are the result of its collaborative company culture and a deep passion for innovation. Genmab’s proprietary pipeline consists of modified antibody candidates, including bispecific T-cell engagers and next-generation immune checkpoint modulators, effector function enhanced antibodies and antibody-drug conjugates. The company is headquartered in Copenhagen, Denmark with locations in Utrecht, the Netherlands, Princeton, New Jersey, U.S. and Tokyo, Japan. For more information, please visit Genmab.com.
Contact:
Marisol Peron, Senior Vice President, Global Investor Relations & Communications
T: +1 609 524 0065; E: mmp@genmab.com
For Investor Relations:
Andrew Carlsen, Vice President, Head of Investor Relations
T: +45 3377 9558; E: acn@genmab.com
This Company Announcement contains forward looking statements. The words “believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with pre-clinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products or technologies obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab’s most recent financial reports, which are available on www.genmab.com and the risk factors included in Genmab’s most recent Annual Report
Genmab A/S | Tel: +45 7020 2728 | Company Announcement no. 37 |
Kalvebod Brygge 43 | www.genmab.com | Page 3/4 |
1560 Copenhagen V, Denmark | | CVR no. 2102 3884 |
| | LEI Code 529900MTJPDPE4MHJ122 |
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
on Form 20-F and other filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov. Genmab does not undertake any obligation to update or revise forward looking statements in this Company Announcement nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law.
Genmab A/S and/or its subsidiaries own the following trademarks: Genmab®; the Y-shaped Genmab logo®; Genmab in combination with the Y-shaped Genmab logo®; HuMax®; DuoBody®; DuoBody in combination with the DuoBody logo®; HexaBody®; HexaBody in combination with the HexaBody logo®; DuoHexaBody®; HexElect®; and UniBody®. Arzerra® and Kesimpta® are trademarks of Novartis AG or its affiliates. DARZALEX® and DARZALEX FASPRO® are trademarks of Janssen Pharmaceutica NV. TEPEZZA® is a trademark of Horizon Therapeutics plc.
Genmab A/S | Tel: +45 7020 2728 | Company Announcement no. 37 |
Kalvebod Brygge 43 | www.genmab.com | Page 4/4 |
1560 Copenhagen V, Denmark | | CVR no. 2102 3884 |
| | LEI Code 529900MTJPDPE4MHJ122 |